Delighted to welcome Dr. David Raben as our Chief Medical Officer. David brings three decades of innovative and targeted oncology drug development expertise, across several therapeutic areas from early stage through approval. Read more about David: ir.pliantrx.com/news-release…

FDA has granted Fast Track designation to PLN-101095 in combination with pembrolizumab for the treatment of ICI-refractory solid tumors. This is supported by Phase 1a data demonstrating anti-tumor activity and a favorable safety profile. ir.pliantrx.com/news-release…

Today, we announced our Second Quarter 2026 Financial Results and provided a company update. Read our press release: ir.pliantrx.com/news-release…

Pleased to name Flavia Borellini, Ph.D. to our Board. Dr. Borellini is a recognized leader in precision oncology drug development and brings more than 25 years of executive biopharma management experience. Read today’s dual appointments press release: ir.pliantrx.com/news-release…

Excited to announce the appointment of Dr. Robert Iannone to our Board. Dr. Iannone is highly accomplished global oncology drug development leader with over two decades of multi-stage clinical drug development expertise. Today’s dual appointments release: ir.pliantrx.com/news-release…

Excited to present FORTIFY to the global oncology community at the 2026 @ASCO ) Annual Meeting. Presentation details: ir.pliantrx.com/news-release…

Today, we announced our First Quarter 2026 Financial Results and provided a company update. Read the press release here: ir.pliantrx.com/news-release…

Pliant team members will be participating in a fireside chat with @RBC Capital Markets’ Brian Abrahams on Tuesday, May 19, 2026 at 11:30 p.m. ET as part of the 2026 RBC Capital Markets Global Healthcare Conference. Details: ir.pliantrx.com/news-release… #RBCHealthcare

First patient dosed in our FORTIFY trial of PLN-101095 in patients with ICI-refractory solid tumors. Read more about FORTIFY, today’s news and how Pliant is focused on addressing underserved areas of medical need: ir.pliantrx.com/news-release…

In an oral presentation today,@UTMDAnderson's Dr. Timothy Yap presented updated results from our Phase 1 trial of PLN-101095 in patients with ICI-refractory solid tumors as part of the @AACR 2026 Annual Meeting. Review the data and presentation lnkd.in/gCvrb5fQ #AACR26

Pleased that data from our Phase 1 clinical trial of PLN-101095 was selected for an oral presentation as part of the Clinical Trials Mini Symposium session at the 2026 @AACR Annual Meeting. Presentation details ir.pliantrx.com/news-release… #AACR26

Today we announced our Fourth Quarter 2025 Financial Results and provided a company update. Review the press release here: lnkd.in/g23DEQ-R

Pliant will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. E.T. at Oppenheimer & Company's 36th Annual Healthcare Life Sciences Conference. #OPCOLifeSciences Details: ir.pliantrx.com/news-release…

Join a collaborative team focused on improving the lives of patients. We are looking for a strategic regulatory leader with extensive oncology expertise to shape the future of our oncology program. Apply here: pliantrx.com/jobs/senior-dir… #Oncology #RegulatoryAffairs #HiringNow

Today we announced encouraging interim data from PLN-101095 in patients with immune checkpoint inhibitor-refractory solid tumors. Press release lnkd.in/gZqX99PC and listen to discussion today at 12:30 pm ET: lnkd.in/gep-MAFx.

Pliant team members will be participating in a fireside chat on Thursday, December 4, 2025 at 12:30 p.m. ET as part of Piper Sandler’s 37th Annual Healthcare Conference. Details: ir.pliantrx.com/news-release…

Today we announced our Third Quarter 2025 Financial Results and provided a company update. Review the press release here ir.pliantrx.com/news-release…

Today, we announced our Second Quarter 2025 Financial Results and provided a company update. Read the press release here: ir.pliantrx.com/news-release…

A productive week at the @atscommunity's 2025 International Conference featured pre-clinical and clinical work from our teams. Learn more and access the presentation and posters ir.pliantrx.com/news-release… #ATS2025

Today, we announced our First Quarter 2025 Financial Results and provided a company update. Read press release here: ir.pliantrx.com/news-release…